Special Diversified Opportunities Inc. (SDOIA)

[raggs]

Strategic Diagnostics Reports Fourth Quarter and Full Year 2008 Results
Significant Year-Over-Year Growth in Genomic Antibody Technology™
NEWARK, Del., February 26, 2009 - Strategic Diagnostics Inc. (Nasdaq: SDIX) - a leading provider of
biotechnology-based detection solutions for a broad range of life science and industrial applications, today reported
financial results for the quarter and year ended December 31, 2008. Revenues for the fourth quarter increased 2% to
$7.0 million, compared to $6.9 million for the third quarter of 2008, and decreased 3% compared to $7.3 million in
the fourth quarter of 2007. Revenues for the fourth quarter of 2008 were positively impacted by a 260% increase in
sales of Genomic Antibody Technology™ (GAT™) products over the comparable prior quarter. The Food
Pathogen and Water and Environmental Product business units showed year-over-year declines in revenues of 2%
and 22%, respectively, for the quarter. The Ag-GMO business unit showed a 12% increase over the comparable
prior quarter
Full year revenues increased 2% to $27.7 million, compared to $27.2 million for 2007. Revenues were positively
impacted by a 155% increase in GAT™ services, a 20% year-over-year increase in Food Pathogen products, as well
as a 2% increase in Water and Environmental products. There was a 6% decline in Ag-GMO revenues from 2007
to 2008.
Francis DiNuzzo, the Company’s Chief Executive Officer, commented, “SDI exhibited solid fourth quarter results
in the midst of a discouraging economic climate. The fourth quarter demonstrated SDI’s continued success in
penetrating the life science marketplace, especially with the key GAT™ technology. We were pleased with our Ag-
GMO business, which delivered a modest 2% increase in overall revenue on a sequential basis, while economic
challenges have adversely affected the markets served by our Food and Water businesses, resulting in a slowdown in
revenue growth. Noteworthy also was a $600,000 improvement in operating income excluding the goodwill
impairment charge this quarter as compared to the third quarter of 2008, demonstrating our commitment to
bringing SDI back to profitability even in challenging market conditions. Despite being faced with considerable
one-time expenses in 2008, we continued to take significant steps towards long-term sustainable growth and profit.
We have made substantial strides over the course of this past year to strengthen the Company’s strategic focus,
operations and leadership. I look forward to continuing to develop our core technology platforms and business
units to penetrate life sciences markets, improve our margins and drive shareholder value. We at SDI have remained
proactive in making significant investments in the life science market and transformations in our management team
to best position the Company for success in 2009.”